Accera Phase III Trial For Alzheimer’s Compound Ketasyn To Focus On ApoE4- Patients
This article was originally published in The Pink Sheet Daily
Executive Summary
Company anticipates launching the Phase III study early in 2008 based on positive Phase II results, CEO Orndorff tells “The Pink Sheet” DAILY.